Dana-Farber Cancer Institute | Strategic Alliance Partners

March 29, 2021

Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

March 20, 2021

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

March 11, 2021

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

March 09, 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the potential clinical implications should belumosudil gain FDA approval in chronic GVHD.

March 03, 2021

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

March 01, 2021

Paul G. Richardson, MD, discusses the FDA approval of melphalan flufenamide in relapsed/refractory multiple myeloma.

February 19, 2021

February 19, 2021 - The National Comprehensive Cancer Network has issued guidelines for the management of children with a rare type of kidney cancer referred to as Wilms Tumor, or nephroblastoma.

February 19, 2021

Patients with metastatic renal cell carcinoma have a new frontline treatment alternative following FDA approval of the combination of nivolumab plus cabozantinib combination.

February 16, 2021

During a recent OncLive Peer Exchange®, a panel of experts in kidney cancer from the United States and France convened to discuss several important immunotherapy studies presented during the ESMO Virtual Congress 2020, as well as several others that are under way and expected to report out over the next few years.

February 15, 2021

February 13, 2021

February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.

February 13, 2021

February 12, 2021

January 30, 2021

January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.

January 29, 2021

January 29, 2021 - Dana-Farber Cancer Institute has announced the launch of its first-ever venture fund, Binney Street Capital, LLC.

January 25, 2021

In our exclusive interview, Toni K. Choueiri, MD, provides perspective on the FDA approval of nivolumab and cabozantinib in advanced renal cell carcinoma.

January 22, 2021

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

January 21, 2021

Elizabeth A. Mittendorf, MD, PhD, discusses patient-reported quality of life associated with neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer.

January 14, 2021

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

January 08, 2021

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.